Intelligent anti-aging skin care based on independent research     
Lose wrinkles, keep your bank account!     
 
Skin Care 101
Skin Care Basics
Skin Protection
Skin Biology
Biology of Aging
Ingredient Guide
Skin & Nutrition
Skin Conditions
 
Anti-Aging Treatments
Topical Actives
Wrinkle Fillers
Noninvasive
Invasive
 
Skin Care Smarts
Smart Choices
Best Practices
Find Good Skin Doc
Quick Tips
Freebie Finder
 
Reviews & Research
Product Reviews
Provider Reviews
Skin Care Research
Clinical Trials
 
How-To Infopacks
Skin Rejuvenation
DIY Skin Care
Skin & Nutrition
Eye Skin Care
Longevity In a Pill
 
Community & Misc
Forums
Polls & Surveys
News and Updates
Search
 
   
You are here: Skin Care Research >

A controlled trial of intralesional recombinant interferon-gamma in the treatment of keloidal scarring. Clinical and histologic findings.

Author: Granstein RD, Rook A, Flotte TJ, Haas A, Gallo RL, Jaffe HS, Amento EP

Author affiliation: Wellman Laboratories, Harvard Medical School, Massachusetts General Hospital, Boston 02114.

Publication date & source: 1990.10, Arch Dermatol., 126(10):1295-302.

Publication type: Clinical Trial; Controlled Clinical Trial; Randomized Controlled Trial

Interferon-gamma (IFN-gamma) suppresses the synthesis of collagen by fibroblasts in vitro and the synthesis of collagen in vivo in animal models. Therefore, recombinant human IFN-gamma was examined for its ability to clinically modify keloids. Subjects were treated by injection of either 0.01 or 0.1 mg of recombinant human IFN-gamma into one lesional site and diluent alone into another lesional site three times per week for 3 weeks. Keloids were measured and photographed before beginning therapy and weekly thereafter. Three days after the final injection, biopsies were performed on treated and control sites. Six of eight subjects who finished the course of treatment demonstrated reduction in size at the treated site with an average reduction in height of 30.4% vs 1.1% for control sites. Lesions treated with recombinant human IFN-gamma demonstrated alterations in both the epidermis and dermis. The epidermis showed thinning of the suprapapillary plates, compact hyperkeratosis, focal or diffuse parakeratosis, exocytosis of lymphocytes, and an increased quantity of mucin. The dermis contained a diminished quantity of thickened collagen bundles and active fibroblasts and an increased number of inflammatory cells and quantity of mucin. These results suggest the feasibility of using IFN-gamma in the treatment of abnormal fibrosis. Dose-ranging studies are required to establish whether IFN-gamma can fulfill a true clinical need in the treatment of keloidal scarring.



Indexes of Skin Care Research Abstracts
by Subject Category Most Recent



Back to Skin Care Research

Google
 
Web SmartSkinCare.com

Home | About Us | Contact Us | Ask a Question | Resources

Copyright © 1999-2009 by Dr. G. Todorov / SmartSkinCare.com
Site Disclaimer | Copyright Certification

   
-- advertisements --